


414 7500 PCT/PTO 27 FEB 2001

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 3552 P 002
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/763908</b>
INTERNATIONAL APPLICATION NO. PCT/GB98/02952	INTERNATIONAL FILING DATE 1 October 1998 (01/10/1998)	PRIORITY DATE CLAIMED 28 August 1998 (28/08/1998)	
TITLE OF INVENTION APPARATUS AND METHOD FOR DETECTING ABNORMALITIES IN BODILY MATTER			
APPLICANT(S) FOR DO/EO/US Wei WANG and Malcolm McCORMICK			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3))</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included</p> <p>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)</p> <p>20. <input checked="" type="checkbox"/> Other items or information</p> <p style="margin-left: 200px;">Express Mail cover sheet; postcard; Check for filing fee; copy of application as published</p>			

U.S. APPLICATION NO. (if known) (37 CFR 1.5)		INTERNATIONAL APPLICATION NO PCT/GB98/02952		ATTORNEY'S DOCKET NUMBER 3552 P 002	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... <b>\$1000.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 860	
				\$ 130	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	22 - 20 =	2	x <b>\$18.00</b>	\$ 36	
Independent claims	4 - 3 =	1	x <b>\$80.00</b>	\$ 80	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$270.00</b>	\$ xxx	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1106	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 553	
<b>SUBTOTAL =</b>				\$ 553	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ xxx	
<b>TOTAL NATIONAL FEE =</b>				\$ 553	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$ xxx	
<b>TOTAL FEES ENCLOSED =</b>				\$ 553	
				<b>Amount to be refunded:</b>	\$
				<b>charged:</b>	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>553</u> to cover the above fees is enclosed.  b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0280</u> . A duplicate copy of this sheet is enclosed.  d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> <b>information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Monique A. Morneault, Esq. WALLENSTEIN & WAGNER, LTD. 311 South Wacker Drive - 5300 Chicago, Illinois 60606 1-312-554-3300				 SIGNATURE  Monique A. Morneault NAME  37,893 REGISTRATION NUMBER	

PTO REGISTRATION PTO 2 / FEB 2001

Attorney Docket No. 3552 P 002

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In Re U.S. Patent Application of:  
WANG/McCORMICK

From: PCT/GB98/02952 and GB 9818790.9

For: A&M FOR DETECTING ABNORMALITIES  
IN BODILY MATTER)  
)  
)  
)  
)  
)  
)**PRELIMINARY AMENDMENT**COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

ATTN: BOX PATENT APPLICATION/WITH FEE

Please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please cancel Claims 1-28 without prejudice.

Please add the following new claims:

29. An electrical tomographic method for detecting abnormalities in bodily matter comprising the steps of:

generating electrical signals at a plurality of frequencies;

applying the electrical signals to the bodily matter using an electrode arrangement;

detecting electrical impedance properties of the bodily matter; and,

using data processing means correlating the detected electrical impedance properties with the presence or absence of abnormalities in the bodily matter using a fractal model of tissue impedance.

30. The method of claim 29 wherein the electrical signals applied to the bodily matter have a frequency greater than 1 MHZ.

31. The method of claim 29 wherein the electrical signals applied to the bodily matter have a frequency greater than 4 MHZ.

32. The method according to Claim 29, wherein the detected electrical impedance properties are selected from the group consisting of  $Z_i$ ,  $Z_x$ ,  $Z_{x_{com}}$ ,  $Z_m$ ,  $Z_{m_{com}}$ ,  $C_m$  and  $C_{m_{com}}$ .

FEB 27 2001 09:59:50

33. The method according to Claim 29, wherein the data processing means correlates detected electrical impedance properties selected from the group consisting of  $Z_{i_{com}}$ ,  $Z_{x_{com}}$  to  $Z_{i_{com}}$  ratio,  $Z_{x_{com}}$ ,  $Z_{m_{com}}$ ,  $C_{m_{com}}$ ,  $Z_{x_{com}} / Z_{m_{com}}$ ,  $Z_{x_{com}} / C_{m_{com}}$ , and  $Z_{m_{com}}$ ,  $Z_{i_{com}}$ .
34. The method according to Claim 29, wherein the data processing means correlates changes and/or large variations of intracellular impedance  $Z_{i_{com}}$  with the presence of dyskaryosis.
35. The method according to Claim 29, wherein the data processing means correlates abnormal  $Z_{i_{com}}$ ,  $Z_{x_{com}}$  to  $Z_{i_{com}}$  ratio with abnormal nuclear-to-cytoplasmic ratio (NCR).
36. The method according to Claim 29, wherein the data processing means correlates abnormal  $Z_{x_{com}}$  with abnormal inter-cellular cohesion.
37. The method according to Claim 29, wherein the data processing means correlates abnormal  $Z_{m_{com}}$ ,  $C_{m_{com}}$ ,  $Z_{x_{com}} / Z_{m_{com}}$ ,  $Z_{m_{com}} / C_{m_{com}}$ ,  $Z_{m_{com}}$ ,  $Z_{i_{com}}$  with abnormal membrane morphology.
38. The method according to Claim 29, wherein the data processing means correlates detected impedance properties selected from the group consisting of:  
i)  $Z_{i_{com}}$ ;  
ii)  $Z_{x_{com}}$ ;  
iii)  $Z_{m_{com}}$ ,  $C_{m_{com}}$ ; and,  
iv) ratio  $Z_{x_{com}} / Z_{i_{com}}$ ;  $Z_{x_{com}} / Z_{m_{com}}$ ;  $Z_{x_{com}} / C_{m_{com}}$ ;  
with the presence of non-infiltrate, early-infiltrate or infiltrate stage cancer.
39. The method of Claim 29, wherein the data processing means references the detected electrical impedance properties of the bodily matter to the detected electrical impedance of other bodily matter.
40. The method according to Claim 37, being adapted to detect a breast carcinoma, wherein the detected impedance properties are of breast tissue and are referenced to detected electrical impedance properties of fatty tissue in the breast.
41. The method according to Claim 29, wherein the data processing means is adapted to compare the detected electrical impedance properties with a database of impedance properties corresponding to bodily matter of known composition.
42. The method of Claim 29, adapted to detect a carcinoma.
43. The method according to Claim 29, adapted to detect a breast carcinoma.

44. The method according to Claim 29, adapted to detect at least one of the group consisting of Stage 3, Stage 2 and Stage 1 carcinomas.
45. The method according to Claim 29, wherein the electrode arrangement is disposed in a woman's brassiere.
46. An electrical tomographic method for detecting abnormalities in bodily matter comprising the steps of:
- generating electrical signals at a frequency greater than 1MHz;
  - applying the electrical signals to the bodily matter using an electrode arrangement;
  - detecting electrical impedance properties of the bodily matter; and,
  - correlating the detected electrical impedance properties with the presence or absence of abnormalities in the bodily matter using a fractal model of tissue impedance as shown in Figures 3 and 4.
47. An electrical impedance tomography apparatus adapted to detect abnormalities in bodily matter comprising:
- an electrical signal generating means for generating electrical signals at a plurality of frequencies;
  - an electrode arrangement for applying the electrical signals to the bodily matter and detecting electrical impedance properties of the bodily matter; and,
  - a data processing means for correlating the detected electrical impedance properties with the presence or absence of abnormalities in the bodily matter using a fractal model of tissue impedance.
48. The apparatus of claim 47 wherein the electrical signals applied to the bodily matter have a frequency greater than 1 MHZ.
49. The apparatus of claim 47 wherein the electrical signals applied to the bodily matter have a frequency greater than 4 MHZ.
50. An electrical impedance tomography apparatus adapted to detect carcinomas in bodily matter comprising:
- an electrical signal generating means for generating electrical signals at a frequency greater than 1 MHZ;
  - an electrode arrangement for applying the electrical signals to the bodily matter and detecting electrical impedance properties of the bodily matter; and,

0976908-0048

Attorney Docket No. 3552 P 002

Title: A&M FOR DETECTING ABNORMALITIES  
IN BODILY MATTER

Page 4

a data processing means for correlating the detected electrical impedance properties with the presence or absence of carcinomas in the bodily matter using a fractal model of tissue impedance as shown in Figures 3 and 4.

09/09/2009 10:00:00

IN THE ABSTRACT:

Please delete the existing Abstract and insert the following:

ABSTRACT

An electrical impedance tomography apparatus and method adapted to detect abnormalities, such as breast carcinomas, is disclosed. The method includes generating electrical signals at a plurality of frequencies, applying the electrical signals to the bodily matter using an electrode arrangement, detecting electrical impedance properties of the bodily matter and, using data processing means, correlating the electrical impedance properties with the presence or absence of abnormalities in the bodily matter using a fractal model of tissue impedance.

No new matter is being added through these amendments. Applicant respectfully requested entry of the above amendments.

Respectfully submitted,

Date: February 27, 2001

By: Monique A. Morneau  
Monique A. Morneau Reg. No. 37,893  
WALLENSTEIN & WAGNER, LTD.  
311 South Wacker Drive - 5300  
Chicago, IL 60606  
1-312-554-3300

smf 117013

Express Mail Label No. EL590261031US

Date of Deposit: February 27, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to:  
COMMISSIONER FOR PATENTS, Washington, D.C. 20231  
(ATTN: BOX PATENT APPLICATIONS/WITH FEE).

Hisan M. Franklin

Apparatus and Method for Detecting  
Abnormalities in Bodily Matter

This invention relates to an apparatus and method for detecting abnormalities in bodily matter, with particular, but by no means exclusive, reference to the detection of breast carcinomas.

Breast cancer is a major cause of mortality in Western countries. In the UK, one in twelve women develop this condition during their lifetime.

Conventionally, screening for breast cancer has employed x-ray mammography. The x-ray images produced thereby are analysed by eye to determine whether any abnormalities are present. Should a potential abnormality be located, further analysis by surgery typically a tissue biopsy, is usually required. Clearly, a non-invasive alternative procedure for investigating breast lesions would be highly desirable. Other disadvantages with x-ray mammography are that ionising radiation is employed, and that identification of lesions from the x-ray image requires a background comprising a substantially contrasting material. As a result, the ability of x-ray mammography to identify low radio-density tumours, and tumours in younger woman, is limited. A further and highly significant disadvantage is that a tumour must be relatively large (for example at least 5 millimetres) before detection is possible with X-ray mammography.

Electrical impedance tomography (EIT) is a well known technique which provides 2 dimensional images or "slices" through an object using an array of electrodes which typically encircle the object. The images are obtained by applying current to the object via selected electrodes, and detecting the potentials generated at other electrodes in the array. The measured potentials depend on the electrical impedance of the object and from these data it is possible to perform a back projection technique to construct an

09763908-054704



image of the electrical impedance of the objects. By performing a plurality of such measurements, both 2- and 3-dimensional image can be assembled.

Dijkstra et al (A. M. Dijkstra, B. H. Brown, A. D. Leathlard, N. D. Harris, D. C. Barber and D. L. Edbrooke; Journal of Medical Engineering & Technology, 17 (1993) 89-98) provides an overview of clinical applications of EIT. Images may be static or dynamic, i.e., representing changes in impedance of the subject over a period of time, an example being an image of the thorax during breathing. It is noted in Dijkstra et al that EIT produces images of body function and not high quality anatomical images. Elsewhere in Dijkstra et al it is commented that static images are technically difficult to produce and that there is no clinical experience with static EIT images. Thus, the teaching of Dijkstra et al is towards the production of dynamic images of body function, and away from the analysis of specific abnormalities, such as carcinomas, via static EIT.

The present invention is concerned with an improved EIT technique which enables non-invasive detection and imaging of abnormalities in bodily matter, a primary, but non-limiting, example of which is the detection and imaging of breast carcinomas.

According to a first aspect of the invention there is provided electrical impedance tomography apparatus adapted to detect abnormalities in bodily matter comprising:

electrical signal generating means for generating electrical signals at a plurality of frequencies;

an electrode arrangement for applying the electrical signals to the bodily matter and detecting electrical impedance properties of the bodily matter; and

data processing means for correlating the detected electrical impedance properties with the presence or absence of abnormalities in bodily matter;

in which electrical signals of a frequency greater than 1 MHz, preferably greater than 2 MHz, more preferably greater than 3 MHz and most preferably greater than 4 MHz, for example 5 MHz, are applied to the bodily matter.

At such high applied frequencies, differences between normal tissue and abnormal tissue are more pronounced, permitting the detection of abnormalities by EIT.

The apparatus may be adapted to detect a carcinoma, which may be a breast carcinoma. In contrast to x-ray mammography, ionising radiation is not employed, and the technique may be successfully applied to younger women and/or to tumours of low radio-density. Furthermore, it is possible to provide a 3 dimensional image, possibly leading to more accurate determination of the position of a carcinoma.

The apparatus may be adapted to detect a stage 3 carcinoma and/or a stage 2 carcinoma and/or a stage 1 carcinoma. These stages are defined in Tables 1 and 2, below.

The data processing means may correlate the detected electrical impedance properties with the presence or absence of abnormalities using a fractal model of tissue impedance.

Information related to dispersion frequencies may be used to perform the correlation.

09763908.1051701  
FOI 150 80669460

The ratio of extra-cellular impedance and intra-cellular impedance may be used to perform the correlation. The ratio of extra-cellular impedance and "membrane" impedance may be used to perform the correlation.

The data processing means may reference the detected electrical impedance properties of the bodily matter to the detected electrical impedance properties of other bodily matter. In the case of breast carcinoma detection, the impedance properties may be referenced to detected electrical impedance properties of fatty tissue or ductal/stroma tissue in the breast.

The data processing means may be adapted to compare the detected electrical impedance properties with a database of impedance properties corresponding to bodily matter of known composition. The database may comprise impedance properties of bodily matter obtained from subjects of differing and known ages, heights, weights or races, or normalised figure.

At least the electrode arrangement may be disposed in a women's brassiere. This permits screening without the physical discomfort associated with x-ray mammography.

According to a second aspect of the invention there is provided an electrical impedance tomographic method for detecting abnormalities in bodily matter comprising the steps of:

generating electrical signals at a plurality of frequencies;

applying said electrical signals to the bodily matter;

detecting electrical impedance properties of the bodily matter; and

correlating the detected impedance properties with the presence or absence of abnormalities in the bodily matter;

in which electrical signals of a frequency greater than 1 MHz, preferably greater than 2 MHz, more preferably greater than 3 MHz and most preferably greater than 4 MHz are applied to the bodily matter.

The abnormality may be a carcinoma, which may be a breast carcinoma.

A stage 3 carcinoma and/or a stage 2 carcinoma and/or and stage 1 carcinoma may be detected.

The correlation of the detected impedance properties with the presence or absence of abnormalities may use a fractal model of tissue impedance.

Information related to dispersion frequencies may be used to perform the correlation.

The ratio of intra-cellular impedance and extra-cellular impedance may be used to perform the correlation. Other ratio smay be used in addition to the extra-cellular vs. intra-cellular impedance. These may include for exmple the intra-cellular impedance divided by the cellular capacitance, which may provide a significant index indicating the abnormality of the tissue. Other ratios which may be used are given in Tables 3-5 (below).

The detection of impedance properties of the bodily matter may be performed at a controlled temperature. The detected electrical impedance properties of the bodily matter may be referenced to detected electrical impedance properties of other bodily matter. In the case of breast carcinoma detection the impedance properties may be referenced to detected electrical impedance properties of other tissues within the breast, for example a normalised response of stroma.

The detected electrical impedance properties may be compared with a database of impedance properties corresponding to bodily matter of known composition. The database may comprise impedance properties of bodily matter obtained from subjects of differing and known ages. The temperature at which readings were obtained and the post-excision age of the bodily matter of the database may also be used in any comparison.

**Table 1: TNM classification and staging for breast cancer**

Classification	Primary tumour (T)
TX	Primary tumour cannot be assessed
TO	No evidence of primary tumour
Tis	Carcinoma in situ (ductal or lobular or Paget's disease with no tumour)
T1	Tumour 2 cm or less in greatest dimension
T1a	0.5 cm or less in greatest dimension
T1b	More than 0.5 cm but not more than 1 cm in greatest dimension
T1c	More than 1 cm but not more than 2 cm in greatest dimension
T2	Tumour more than 2 cm but not more than 5 cm in greatest dimension
T3	Tumour more than 5 cm in greatest dimension
T4	Tumour of any size with direct extension to chest wall or skin
T4a	Extension to chest wall
T4b	Edema (including peau d'orange) or ulceration of skin breast or satellite skin nodules confined to same breast
T4c	Both (T4a and T4b)
T4d	Inflammatory carcinoma

	Regional lymph nodes (pathologic pN)
pNX	Regional nodes cannot be assessed
pNO	No regional node metastases
pN1	Metastases to movable ipsilateral axillary nodes
pN1a	Micrometastases only (none larger than 0.2 cm)
pN1b	Metastasis to node(s), any larger than 0.2 cm
pN1bi	Metastasis in 1 to 3 nodes, any more than 0.2 cm and all less than 2 cm in greatest dimension
pNbii	Metastasis to 4 or more nodes, any more than 0.2 cm and all less than 2 cm in greatest dimension
pNbiii	Extension of tumour beyond node capsule; metastasis less than 2 cm in greatest dimension
pNbiv	Metastasis greater than 2 cm in greatest dimension to a node
pN2	Metastasis to ipsilateral axillary nodes that are fixed to one another or to other structures
pN3	Metastasis to ipsilateral internal mammary nodes
	Distant metastasis (M)
MX	Presence of distant metastasis cannot be assessed
MO	No distant metastases
M1	Distant metastasis (includes metastasis to ipsilateral supraclavicular nodes)

**Table 2: Stage Group for Breast Cancer**

Stage 0	Tis	N0	M0
Stage 1	T1	N0	M0
Stage IIA	T0	N1	M0
	T1	N1	M0
	T2	N0	M0
Stage IIB	T2	N1	M0
	T3	N0	M0
Stage IIIA	T0	N2	M0
	T1	N2	M0
	T2	N2	M0
	T3	N1	M0
	T3	N2	M0

Stage IIIB	T4	Any N	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1

(Source: American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC)1992)

Methods and apparatus in accordance with the invention will now be described with reference to the accompanying drawings, in which:-

- Figure 1 is a schematic diagram of an EIT apparatus;
- Figure 2 shows a cross sectional view of a female human breast;
- Figure 3 shows micro-level equivalent circuits - a) an equivalent circuit of a single cell, b) an equivalent circuit of a group of cells, c) an equivalent circuit of a number of groups of cells;
- Figure 4 shows a) an equivalent circuit of a number of groups of cells, b) the effective equivalent circuit for a number of groups of healthy cells, c) the effective equivalent circuit for a number of groups of diseased cells; and d) an equivalent circuit for a number of circuits of Figure 4(a); and
- Figure 5 shows a micro-range model of a ductal system.

Figure 1 shows EIT apparatus adapted to detect abnormalities in bodily matter 10 comprising:

electrical signal generating means 12 for generating electrical signals at a plurality of frequencies;

an electrode arrangement 14 for applying the electrical signals to the bodily matter 10, and detecting electrically impedance properties of the bodily matter 10; and

data processing means 16, 18, 20 for correlating the detected electrical impedance properties with the presence or absence of abnormalities in the bodily matter 10;

in which electrical signals of a frequency greater than 1MHz, preferably greater than 2MHz, more preferably greater than 3MHz and most preferably greater than 4MHz are applied to the bodily matter.

At these high applied frequencies, differences between normal tissue and abnormal tissue are more pronounced, permitting the detection of abnormalities by EIT. It should be noted that the range of applied frequencies are certainly not restricted to this high frequency range. Indeed, it is preferably to utilise a wider bandwidth - in a representative example, frequencies in the range 1kHz to 5 MHz are applied. Typically a number of spot frequencies across the desired bandwidth are applied, in sequential manner, to the bodily matter. However, it should be noted that the use of time-to-frequency techniques is also within the scope of the invention. In this instance, an appropriate time varying waveform is applied to the electrode arrangement, and the response is monitored as a function of time. The time varying waveform can be considered to comprise electrical signals at a plurality of frequencies. The (time domain) response is then transformed into the frequency domain by an appropriate technique, such as a fast Fourier transform (FFT).



In the present, non-limiting example, the electrical signal generating means 12 comprises a high impedance current source, converting the voltage output of a fully programmable Direct Digital Synthesis (DDS) 50 MHz microchip. An artificial upper limit of 5 MHz is placed on the output frequency, so that the waveform can be synthesised by the DDS chip in ten steps. Higher frequencies might be produced if desired - in principle, a 25 MHz "square" wave can be produced. Current is injected into the electrode arrangement 14, which is of the type well known in the tomographic field, comprising a set of current injection electrodes interlaced with voltage detection electrodes. A 2-dimensional thirty two electrode arrangement (comprising sixteen current injection electrodes and sixteen voltage detection electrodes) and a 1-dimensional four electrode arrangement have been used. The thirty two electrode system provides superior spatial resolution when the electrode systems are of identical dimensions. Detection of the voltage developed at the electrodes is performed using an EIT analogue hardware processing system 16. Data are then digitised by an analogue to digital convertor 18 and transferred to a computer 20 where the data can be stored and processed by a software system base upon commercially available products. The software system firstly collects the raw data from the electrodes and then a signal processing technique is applied to it to remove artefacts such as those caused by electrode-tissue contact problems, EIT system noise and system calibration. A filtered back-projection image method (Prof. David Barker, University of Sheffield) is then used to reconstruct an image. Image analysis is then performed to extract data from the reconstructed image, and the data is then correlated to that in a database containing data for normal and abnormal tissues having been normalised for patient parameters including weight, age and body fat content, and the degree of correlation for the various tissue types determined in order to ascertain the probable nature of the tissue from the sections of the projected data. The software can retrieve data, convert the data to an impedance measure and reconstruct the data to produce a pixelated image.

Although the apparatus and method of the present invention might be used to detect many abnormalities, such as ulcers and thrombosis, a primary example is in the detection of carcinomas. As discussed previously, a particularly important example is the detection of breast carcinomas, more particularly early-stage breast carcinomas.

Figure 2 shows sections through a human breast. Glandular tissue, shown generally at 22, is mainly located under the mammary papilla 24 and areola. The glandular tissue consists of a system of terminal ducts 26 which penetrate deep into the fibroadipose tissue of the breast. Each of the ducts is lined by columnar or cuboidal epithelium, comprising a continuous surface layer of epithelial cells with oval nuclei and an outer discontinuous layer of myoepithelial cells which have clear cytoplasm. The ducts 26 branch into ductules 28 and end in lobes 30. Additionally, there are regions of the breast in the lower and upper quadrants which consist of fat and muscle, and have no underlying glandular tissue. However, these regions are rarely host to any disease. In fact, cancer of the glandular tissue is the most common form of breast disease, of which infiltrating ductal carcinoma comprises 84% and infiltrating lobular carcinoma comprises 10% of all cases.

An important aspect of the present invention is the two-tier fractal or cascaded model of tissue impedance that is used to interpret the EIT measurements. Figure 3a shows a RRC cascade equivalent circuit of a single cell, comprising a series and parallel arrangement of intra-cellular impedance  $Z_i$  (111) comprising intra-cellular capacitance  $C_i$  (112), intra-cellular resistance  $S_i$  (113) and intra-cellular cross-resistance  $R_i$  (114); extracellular impedance  $Z_x$  (121) comprising extra-cellular fluid capacitance  $C_x$  (122), extra-cellular resistance  $S_x$  (123) and extra-cellular cross resistance  $R_x$  (124); and RRC membrane model  $Z_m$  (101) comprising cell membrane capacitance  $C_m$  (102), membrane resistance  $S_m$  (103) and cross-membrane resistance  $R_m$  (104). If, as shown in Figure 3a, this cellular equivalent circuit is denoted by the block "Zcell", then a group of cells can be represented by the circuit shown in Figure 3b, and there may be multiple

cascading levels of this circuit. In this circuit, groups of individual cellular components  $Z_{\text{cell}}$  are represented by a cascaded arrangement. The equivalent circuit of the combined cells shown in Figure 3b is denoted by the block " $Z_{\text{com}}$ ". A still larger volume of tissue can be described by the equivalent circuit shown in Figure 3c, in which the blocks " $Z_{\text{com}}$ " are arranged in a different cascaded configuration to that shown in Figure 3b. The process can be repeated to produce equivalent circuits for larger and larger cell groupings.

The fractal model of Figures 3a and 3b are applicable to breast tissue at a "micro" level scale (application to distances of up to about 100  $\mu\text{m}$ ), typically representing single cells, basic compound cells/tissue units, and compound tissues. At a "macro" level (applicable to distances in excess of about 100  $\mu\text{m}$ ) a different fractal model, namely that of Figures 3b and 4, is appropriate and is capable of representing compound tissues, integral single type cells and integral compound type cells. The exact distances at which the micro and macro models apply will differ slightly from tissue to tissue, and the exact cut-off point for a particular tissue may be readily determined by one skilled in the art. Where the "micro" and "macro" scale fractal models interact (i.e. at approximately 100  $\mu\text{m}$  distances) the  $Z_{\text{com}}$  units are the same. Thus a "micro" level fractal model  $Z_{\text{com}}$  unit is used as a "macro" level fractal model  $Z_{\text{com}}$  unit. This is referred to as the "ICI" model of integrated cell impedance. Thus, the overall model of tissue impedance is a fractal one, in the sense that the equivalent circuit at any give scale comprises sub-units in a common arrangement, and each of the sub-units itself comprises smaller sub-units which are also in the same common arrangement (i.e. the cascaded arrangement of Figures 3 and 4).

The fractal model of tissue impedance takes account of the physiological constitution of the cell/compound tissue/organ/system hierarchy. Furthermore, there is a direct relationship between the fractal model used and the resolution of the EIT system employed - for example, at very high resolution the EIT technique might provide pixels

Cancerous tissue gives rise to different electrical characteristics than those exhibited by normal, healthy tissue. Consider the equivalent circuit of the multi-cellular structure shown in Figure 4a. In normal tissue, the potential across the central Zcom block 32 is around 0V. Under these conditions, the multi-cellular impedance can be represented by a single Zcom block, as shown in Figure 4b. As a result, the number of dispersion (or corner) frequencies associated with the tissue will be constant, the ratio of intra and extra-cellular impedance (XIR) and the ratio of extra-cellular and membrane impedance (capacitance), XMR, will be constant.

In contrast, in diseased tissue there is a significantly non-zero potential across the central Zcom block. Under these circumstances, the electrical characteristics, for example dispersion characteristics, will be altered compared to normal tissue. In particular, the diseased tissue exhibits additional dispersions together with changes of XIR and XMR due to variations between the cascaded (parallel) Zcom blocks. Thus, detection of these additional dispersions, XIR and XMR (which might be overlaid) are indicative of the presence of diseased tissue and may be related to changes in the epithelium (degree of disruption of membrane base e.g. ductal/lobular system). Figure 4c shows a representative equivalent circuit, although it should be noted that it may be appropriate to describe the tissue impedance with additional parallel components, such

as that shown in broken lines in Figure 4c. Tables 3 to 5 describe the correlation between detected electrical impedance properties and breast carcinoma pathology.

**Table 3a. Matched Pathological/Electrical Parameters for Cancer Detection (in cellular range)**

Pathological properties of cancer cells	Electrical Properties of Cancer Cells (non-limiting)
1. Dyskaryosis	Changes and/or large variations of intra-cellular impedance $Z_{i_{com}}$
2. Abnormal nuclear-to-cytoplasmic ratio (NCR)	abnormal $Z_{i_{com}}$ , $Z_{x_{com}}$ to $Z_{i_{com}}$ ratio
3. Abnormal inter-cellular cohesion	abnormal $Z_{x_{com}}$
4. Abnormal membrane morphology	abnormal $Z_{m_{com}}$ , $C_{m_{com}}$ , $Z_{x_{com}} / Z_{m_{com}}$ , $Z_{x_{com}} / C_{m_{com}}$ , $Z_{m_{com}} \cdot Z_{i_{com}}$

Notes:

$Z_i$  - intra-cellular impedance of single cell

$Z_{i_{com}}$  - integral intra-cellular impedance among the cells

$Z_x$  - extra-cellular impedance of single cell

$Z_{x_{com}}$  - integral intra-cellular impedance among the cells

$Z_m$  - membrane impedance of single cell

$Z_{m_{com}}$  - integral membrane impedance among the cells

$C_m$  - membrane capacitance of single cell

$C_{m_{com}}$  - integral membrane capacitance among the cells

**Table 3b. Matched Pathological/Electrical Parameters for Cancer Detection (in compound tissue/compound cell range)**

Pathological properties of cancer cells	Electrical Properties of Cancer Cells (non-limiting)

**Table 4. Matched Pathological/Electrical parameters for Early Stage (non-infiltrate) Cancer Detection**

Pathological properties of early stage ductal/lobular cancers	Electrical Properties of the early stage ductal/lobular cancers
1. changes and /or variation of intra-ductal/intra-lobular structures	changes of intra-ductal/intra-lobular impedance $Z_{i_{com}}$  variation of $Z_{i_{com}}$ (dependent on cancer types)
2. changes and /or variation of extra-ductal/extra-lobular structures	changes extra-ductal / extra-lobular impedance $Z_{x_{com}}$
3. changes and /or variation of "basement membrane" of ductal/lobular structure	changes "basement membrane" impedance $Z_{m_{com}}$ , $C_{m_{com}}$ (additional dispersion become evident)
4. Abnormal morphology of extra-to-intra relationship of ductal/lobular structure	abnormal extra-to-intra ductal/lobular impedance ratio $Z_{x_{com}} / Z_{i_{com}}$ ; $Z_{x_{com}} / Z_{m_{com}}$ ; $Z_{x_{com}} / C_{m_{com}}$

**Table 5. Matched Pathological/Electrical parameters for Late Stages (Early-infiltrate and infiltrate stage) Cancer Detection**

Pathological properties of Late Stage cancers	Electrical Properties of the Late Stage ductal/ lobular cancers
1. changes and /or variation of intra-ductal/intra-lobular structures	changes of intra-ductal/intra-lobular impedance $Z_{i_{com}}$  variation of $Z_{i_{com}}$ (dependent on cancer types)
2. changes and /or variation of extra-ductal/extra-lobular structures	changes extra-ductal / extra-lobular impedance $Z_{x_{com}}$
3. penetration and /or larger variation of "basement membrane" of ductal/lobular structure	significantly change "basement membrane" impedance and capacitance $Z_{m_{com}}$ , $C_{m_{com}}$ (additional dispersions becoming significant)
4. Abnormal morphology of extra-to-intra relationship of ductal/lobular structure	abnormal extra-to-intra ductal/lobular impedance ratio $Z_{x_{com}} / Z_{i_{com}}$ ; $Z_{x_{com}} / Z_{m_{com}}$ ; $Z_{x_{com}} / C_{m_{com}}$

In intraductal or in-situ breast cancer, the malignant cells proliferate within the existing ductal system without destruction of the surrounding basement membrane. An example is lobular carcinoma in-situ (LCIS). LCIS is characterised by filling of the lobules with relatively small, uniform cells. Invasive lobular carcinoma has a tendency to spread diffusely between collagen fibres. Figure 5 shows a micro-range model of a ductal system for the detection of early stage ductal carcinoma - a similar model describes lobular carcinoma. In Figure 5, block 50 represents a RRC circuit for ductal basement (epithelial) wall membrane, block 52 represents a RRC circuit for intraductal (integral) impedance including the nucleus and block 54 represents a RRC circuit for extraductal impedance. Block 50 comprises membrane capacitance 56, membrane resistance 58 and cross membrane resistance 60. Block 52 comprises intraductal capacitance 62, intraductal resistance 64 and intraductal cross resistance 66. Block 54 comprises extraductal capacitance 68, extraductal resistance 70 and extraductal cross resistance 72.

In correlating the detected electrical impedance properties with the presence or absence of abnormalities such as carcinomas, it is advantageous to reference the detected impedance properties of the bodily matter to the detected electrical impedance properties of other bodily matter. This referencing procedure might comprise deriving a difference spectrum by subtracting "standard" responses from the measured responses. In the detection of breast carcinomas, it is useful to reference the impedance properties to the detected impedance properties of fatty tissue in the breast, although the referencing might alternatively be with respect to normal gland tissue. A self referencing technique can be employed, in which high impedance fatty areas are masked from the image, followed by normalisation of the remaining data relative to a chosen frequency, such as 1kHz.

In a different approach, higher order differentials (such as second order differentials) of change in impedance are analysed at low and high frequencies and can

give useful information for e.g. tumorous tissues and the surrounding fatty and stroma tissues.

Numerous factors affect the measured impedance properties. An important factor is the temperature at which the measurement is made. This might be accounted for by building the temperature dependence into the correlation step, or preferably, by controlling the temperature at which the measurement is made. When *in vitro* measurements were performed on samples of tissue excised from a breast, it was found that the detected impedance properties vary depending on the orientation of the tissue, i.e. whether the current flow through the tissue is parallel or perpendicular to the excision. An additional factor was the fresh tissue handling procedure used - fresh blood-free tissue ensured a reduction in the unexpected deviation between samples.

Another important factor in the detection of breast carcinomas is the age of the subject. Body size is also important. Both of these factors are linked with body fat and water content. It is possible to account for the variations by compiling a database of impedance properties corresponding to bodily matter of known composition, in particular consisting of measurements made from different subjects, having known breast fat content or, more practically, of known age. The database might comprise a library of such responses, or it might comprise an artificial intelligence system, such as a trained neural network.

*In vitro* measurements have been performed on a number of breast tissue samples supplied via a clinical collaboration with Glenfield General Hospital, Groby Road, Leicester, UK. Statistically significant differentiation was found between normal and stage 2 and stage 3 infiltrating ductal carcinomas. It has not proved possible to show significant *in vitro* differentiation between stage 1 or earlier cancers and normal tissues at the present time. This has been due, as discussed above, to difficulties in the identification of such carcinomas conventionally, and therefore it is extremely difficult



to obtain sufficient numbers of such samples in the first instance. It is believed that the present invention will be able to detect stage 1 or earlier carcinomas, provided the spatial resolution of the interrogating EIT is commensurate with the small physical dimensions of these earlier stage tumours. This represents a major advantage over X-ray mammography.

It is highly desirable to perform *in vivo* detection since this is non-invasive. One way in which this might be performed in order to detect or screen for breast carcinomas is to dispose at least the electrode arrangement in a woman's brassiere. Such an arrangement can be made comfortable for the subject to wear. Furthermore, by disposing a plurality of electrode arrays in the brassiere, three dimensional images can be produced.

0953908 051701

## CLAIMS

1. Electrical impedance tomography apparatus adapted to detect abnormalities in bodily matter comprising:

electrical signal generating means for generating electrical signals at a plurality of frequencies;

an electrode arrangement for applying the electrical signals to the bodily matter and detecting electrical impedance properties of the bodily matter; and

data processing means for correlating the detected electrical impedance properties with the presence or absence of abnormalities in the bodily matter;

in which electrical signals of a frequency greater than 1 MHz, preferably greater than 2 MHz, more preferably greater than 3 MHz and most preferably greater than 4 MHz are applied to the bodily matter.

2. Apparatus according to claim 1 adapted to detect a carcinoma.
3. Apparatus according to claim 2 adapted to detect a breast carcinoma.
4. Apparatus according to claim 2 or claim 3 adapted to detect a stage 3 carcinoma.
5. Apparatus according to any of claims 2 to 4 adapted to detect a stage 2 carcinoma.

6. Apparatus according to any of claims 2 to 5 adapted to detect a stage 1 carcinoma.
7. Apparatus according to any previous claims in which the data processing means correlates the detected electrical impedance properties with the presence or absence of abnormalities using a fractal model of tissue impedance.
8. Apparatus according to any previous claim in which information related to dispersion frequencies is used to perform the correlation.
9. Apparatus according to any previous claims in which the ratio of intra cellular impedance and extra cellular impedance is used to perform the correlation.
10. Apparatus according to any previous claims in which the data processing means references the detected electrical impedance properties of the bodily matter to the detected electrical impedance properties of other bodily matter.
11. Apparatus according to claim 10 when dependent on claim 3 in which the impedance properties are referenced to detected electrical impedance properties of fatty tissue in the breast.
12. Apparatus according to previous claim in which the data processing means is adapted to compare the detected electrical impedance properties with a database of impedance properties corresponding to bodily matter of known compositions.
13. Apparatus according to claim 12 in which the database comprises impedance properties of bodily matter obtained from subjects of differing and known ages.

14. Apparatus according to any previous claims in which at least the electrode arrangement is disposed in a women's brassiere.
15. An electrical tomographic method for detecting abnormalities in bodily matter comprising the steps of:
  - generating electrical signals at a plurality of frequencies;
  - applying said electrical signals to the bodily matter;
  - detecting electrical impedance properties of the bodily matter; and
  - correlating the detected impedance properties with the presence or absence of abnormalities in the bodily matter;in which electrical signals of a frequency greater than 1 MHz, preferably greater than 2 MHz, more preferably greater than 3 MHz and most preferably greater than 4 MHz are applied to the bodily matter.
16. A method according to claim 15 in which the abnormality is a carcinoma.
17. A method according to claim 16 in which the abnormality is a breast carcinoma.
18. A method according to claim 16 or claim 17 in which a stage 3 carcinoma is detected.

19. A method according to any of claim 16 to 18 in which a stage 2 carcinoma is detected.
20. A method according to any of claims 16 to 19 in which a stage 1 carcinoma is detected.
21. A method according to any of claims 15 to 20 in which the correlation of the detected impedance properties with the presence or absence of abnormalities uses a fractal model of tissue impedance.
22. A method according to any of claims 15 to 21 in which information related to dispersion frequencies is used to perform the correlation.
23. A method according to any of claims 15 to 22 in which the ratio of intra-cellular impedance and extra-cellular impedance is used to perform the correlation.
24. A method according to any of claims 15 to 23 in which the detected electrical impedance properties of the bodily matter are referenced to detected electrical impedance properties of other bodily matter.
25. A method according to claim 24 when dependent on claim 17 in which the impedance properties are referenced to detected electrical impedance properties of fatty tissue in the breast.
26. A method according to any of claim 15 to 25 in which the detected electrical impedance properties are compared with a database of impedance properties corresponding to bodily matter of known composition.

27. A method according to claim 26 in which the database comprises impedance properties of bodily matter obtained from subject of differing and known ages.

28. A method according to any of claims 24 to 27 in which the the detected electrical impedance properties of the bodily matter are referenced or compared to impedance properties of other bodily matter of a controlled temperature.




FIG. 1




FIG. 2




FIG. 5









FIG. 3



FIG. 4

Attorney File No. 3552 P 002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECLARATION AND POWER OF ATTORNEY

As a below-named Inventors, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole Inventor or original, first and joint Inventors of the subject matter which is claimed and for which a patent is sought on the invention titled **Apparatus and Method for Detecting Abnormalities in Bodily Matter**, the specification of which:

\_\_\_\_\_ is attached hereto  
  X   was filed on 1 October 1998 as International Application  
No. PCT/GB98/02952; or,  
\_\_\_\_\_ was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information of which I am aware is material to the examination of the application in accordance with 37 CFR §1.56(a).

I hereby claim foreign priority benefits under 35 USC §119 of any foreign application(s) for patent or Inventor's certificate listed below and have also identified below any foreign application for patent or Inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): GB 9818790.0

I hereby claim the benefit under 35 USC §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35

USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: \_\_\_\_\_

I hereby claim the benefit under 35 USC §119(c) of any United States provisional application listed below: \_\_\_\_\_

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY



As named Inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.


23  
Thomas K. Stine (32,310)  
James J. Jagoda (33,250)  
Micheal D. Lake (33,727)  
Linda A. Kuczma (30,861)  
Richard C. Himelhoch (35,554)  
Monique A. Morneault (37,893)  
Paul J. Nykaza (38,984)  
Robert W. Diehl (35,118)  
Matthew J. Gryzlo (43,648)  
Joseph M. Kinsella (45,743)  
William J. Lenz (44,208)  
Christopher S. Clancy (44,618)

Daniel N. Christus (29,626)  
Edward L. Bishop (39,110)  
Roger H. Stein (31,882)  
Joseph A. Fuchs (34,604)  
Bradley F. Rademaker (35,331)  
Jeffrey R. Gargano (38,148)  
James P. Muraff (39,785)  
Nelson Nolte (42,938)  
Brent A. Hawkins (44,146)  
Peter M. Klobuchar (43,722)  
Michael K. Nutter (44,979)

Send correspondence and direct telephone calls to:


Monique A. Morneault, Esq.  
WALLENSTEIN & WAGNER, LTD.  
311 South Wacker Drive, 53rd Floor  
Chicago, Illinois 60606  
(312) 554-3300

Full Name of Sole or First Joint Inventor: Wei Wang  
Residence: Great Britain  
Citizenship: Chinese  
Post Office Address: 23 Fairstone Hill, Oadby, Leicester, LE2 5RL, GB

Inventor's Signature: 

Date: 11-4-2001

200  
Full Name of Second Joint Inventor: Malcolm McCormick  
Residence: Great Britain  
Citizenship: British  
Post Office Address: 125 Knowle Lane, Sheffield, S11 9SN, GB

Inventor's Signature: 

Date: 11 April 2001